Navigation Links
CVS Caremark Research Finds Medication Adherence Can Improve Outcomes and Reduce Costs for Patients with Coronary Artery Disease
Date:3/19/2013

WOONSOCKET, R.I., March 19, 2013 /PRNewswire/ -- Heart disease costs the United States $108.9 billion each year according to the Centers for Disease Control, but there are ways those costs can be controlled. Research published in the April issue of the American Journal of Medicine found that patients with coronary artery disease (CAD) who are adherent to their prescribed medications can save the health care system up to $868 per patient per year.  The study, conducted by researchers at Brigham and Women's Hospital and CVS Caremark (NYSE: CVS), found a consistent trend toward improvement in coronary artery-related events, mortality, readmissions, and costs among those patients who most adhered to their medication regimens.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO )

"Managing rising health care costs is the most pressing issue facing our health care system today," said Troyen A. Brennan, MD, MPH, Executive Vice President and Chief Medical Officer of CVS Caremark. "This study affirms a consistent trend we have seen in research regarding the positive effect of improving medication adherence. Patients with chronic conditions are healthier when they adhere to their prescribed medication regimens and, as a result, the costs associated with their care are reduced."

In the study, entitled "The Impact of Medication Adherence on Coronary Artery Disease Costs and Outcomes: A Systematic Review," the researchers reviewed over 2500 studies published between 1966 and 2011, analyzing in detail the 25 studies that met the inclusion criteria related to adherence and coronary artery disease outcomes. A subset of the studies measured the impact of medication adherence on primary prevention of CAD and the remainder focused
'/>"/>

SOURCE CVS Caremark
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
2. CVS Caremark Reports Record First Quarter Results
3. CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
4. CVS Caremark Research Identifies Positive Link Between Medication Adherence and Employee Productivity
5. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
6. CVS Caremark To Present At Goldman Sachs 2012 Global Retailing Conference
7. CVS Caremark to Present at Morgan Stanley Global Healthcare Conference
8. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $6 Billion of Common Stock
9. CVS Caremark Donates More Than $100,000 to Hurricane Sandy Relief Efforts
10. CVS Caremark To Present At Lazard Capital Markets 9th Annual Healthcare Conference
11. CVS Caremark Reports Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... DIEGO , Sept. 2, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... be participating in the Morgan Stanley Healthcare conference ... by Scott Huennekens , president and chief ...
(Date:9/2/2014)... Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... products marketed as XIAFLEX ® in the U.S. and ... President, Tom Wegman , will present at the following ... Rodman & Renshaw 16 th Annual ... Tuesday, September 9, 2014 at 9:10 a.m. EDT ...
(Date:9/2/2014)... , September 2, 2014 ... NASDAQ: EMITF ) announced today following the ... Technologies Ltd. ("Elbit Medical") (TASE: EMTC-M), a subsidiary of ... a fully diluted basis, announced that on September 1, ... approximately 30.8% of the voting power ("Gamida Cell") and ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company 3
... Phase IIa Trial Increase in Dendritic, ... BASKING RIDGE, N.J., Oct. 10 VioQuest,Pharmaceuticals ... company focused on acquiring, developing and,commercializing targeted ... enrollment in its Phase I open-label dose ...
... New Phase 3 Plan Could Expedite Clinical Development Pathway, ... (Nasdaq: ANSV ) today announced that it will ... Adlea(TM) -- one of which has already,been planned in ... in,bunionectomy surgeries -- for a broad product label of ...
Cached Medicine Technology:VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM) 2VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM) 3VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM) 4Anesiva Defines Regulatory Pathway for Adlea with FDA 2Anesiva Defines Regulatory Pathway for Adlea with FDA 3Anesiva Defines Regulatory Pathway for Adlea with FDA 4Anesiva Defines Regulatory Pathway for Adlea with FDA 5
(Date:9/2/2014)... (HealthDay News) -- The quality of Americans, diets has ... between the rich and poor is growing, a new ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ... a doctoral student in the department of nutrition at ...
(Date:9/2/2014)... Amy Norton HealthDay ... For people who want to lose weight and boost their ... trimming dietary fat, a new study suggests. In a ... assigned to follow a low-carbohydrate diet lost more weight over ... They also had bigger improvements in their cholesterol and triglyceride ...
(Date:9/2/2014)... 02, 2014 The Jerry Segal Classic ... on September 19 at The ACE Club and Green ... past 25 years, the Classic, organized by the Friends ... for programs and services designed to support patients and ... , “The Segal Classic is a labor of ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 North ... America Resectoscopes Market Outlook to 2020? provides key ... The report provides value, in millions of US ... US dollars) within market segments –, ... (Disposable and Reusable) Electrodes and Bipolar (Disposable and ...
(Date:9/2/2014)... Ohio (PRWEB) September 02, 2014 Humility of ... Home, Sept. 18 at St. Elizabeth Health Center, 1044 Belmont ... provides information about more than 200 common health problems as ... preventing illness and injury, and advice on when to seek ... a.m. to noon in the Youngstown Room; the evening session ...
Breaking Medicine News(10 mins):Health News:Quality of U.S. Diet Improves, Slightly 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:HMHP Offers ‘Health at Home’ Workshop 2
... Barcelona, Spain: An experimental drug that attacks cancer in ... advanced melanoma, delaying progression of the disease and prolonging ... (Wednesday) at the European Cancer Conference (ECCO 14) in ... to chemotherapy more than doubled the amount of time ...
... 26 Biomedtex Inc.,(Pink Sheets: PDNL.PK) ("Biomed" or ... that A. Marc Rocca, 42, will be,President and ... mission is to identify, evaluate and assess a ... and then,seek to capture and promote innovations with ...
... Nycomed Acquires Exclusive Rights Outside North America in Deal Valued ... ... N.J. and ZURICH, Switzerland, Sept. 26, NPS Pharmaceuticals, Inc. (Nasdaq: ... into a definitive agreement,which licenses to Nycomed the rights to ...
... research has yielded a clearer picture of which biomarkers ... colon cancer, bringing closer the day when patients who ... those that will, get the more aggressive treatment they ... doctors plan treatment of colon cancer chiefly by staging ...
... work investigating the reproducibility of glycemic index values, ... Research Center on Aging at Tufts University (USDA ... determinations (measure of the rate of glucose absorption ... white bread, resulted in a relatively high level ...
... to Home and the ... ... pioneer and largest provider of retail-,based health care in the United ... stores in Southeastern,Pennsylvania and Southern New Jersey. MinuteClinic plans to open ...
Cached Medicine News:Health News:New type of drug shows promise in attacking melanoma in an innovative way 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2Health News:Glycemic index values are variable, report researchers 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 3Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 4Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: